Recent Advances in the Development of Dual Topoisomerase I and II Inhibitors as Anticancer Drugs
In this regard, a single compound able to inhibit both Topo I and II may present the advantage of improving antitopoisomerase activity, with reduced toxic side effects, with respect to the combination of two inhibitors. Due to the high interest in such compounds, this review represents an update of previous works dealing with the development of dual Topo I and II inhibitors as novel anti-cancer agents. The newly collected derivatives have been described focusing attention on their chemical structures and their biological profiles.
Keywords: Amsacrine; Anticancer drugs; Antiproliferative activity; Apigenin; Batracylin; Camptothecin; Camptothecins; Carboplatin; Curcumin; DNA; Daunorubicin (DAU); Diflomotecan; Doxorubicin; Dual inhibitor; Ellipticine 5; Etoposide; Fisetin; G2/M phases; Gimatecan; HL-60 human promyelocytic leukaemic cells; Irinotecan; MDR phenomena; MTDs; Mitoxanthrone; Myricetin; Paclitaxel; Phenazine Derivatives; Prodigiosin; Quinolones; S. marcescens; Tafluposide; Tilia amurensis; Topisomerase IV; Topoisomerase I; Topoisomerase II; Topopyrones; Topotecan; adenocarcinomas; anemia; apoptosis; cardiotoxicity; chromatin remodeling; chromophore; cisplatin; cytotoxic; enzymes; human leukaemia cells (CEM); leukaemia; malignant; neutropenia; pharmacokinetics; pluramycins; recombination; replication; solid tumours; transcription; xenografts
Document Type: Research Article
Publication date: 2010-12-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.